Anti-CD123 CAR-NK-92

Anti-CD123 CAR-NK-92 is an allogeneic, off-the-shelf chimeric antigen receptor (CAR) natural killer (NK) cell therapy developed at Hannover Medical School for the treatment of acute myeloid leukemia (AML). The therapy utilizes the established NK-92 cell line, which is genetically modified using alpharetroviral vectors to express a third-generation CAR targeting CD123 (interleukin-3 receptor subunit alpha). CD123 is highly and consistently expressed on AML blast cells and leukemic stem cells, making it a viable target for cellular immunotherapy. The CAR construct includes costimulatory domains from CD28 and 4-1BB, alongside the CD3ζ signaling domain to optimize activation. To address the typical limitations of NK cell persistence in vivo, the cells are further engineered to constitutively express human Interleukin-15 (IL-15), which provides autonomous survival signals through the IL-15 receptor. Preclinical studies have demonstrated enhanced cytotoxicity and anti-tumor activity against CD123+ AML cell lines and patient-derived xenograft models.

Other names

Anti-CD123-CAR-NK-92-IL-15Anti-CD-123-CAR-NK-92-IL-15Anti-CD 123-CAR-NK-92-IL-15CD123 CAR-NK-92CD-123 CAR-NK-92CD 123 CAR-NK-92Hannover Medical School CD123 CAR-NK